Frazier Life Sciences Management
Latest statistics and disclosures from Frazier Life Sciences Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MIRM, NAMS, ERAS, MBX, ARQT, and represent 56.53% of Frazier Life Sciences Management's stock portfolio.
- Added to shares of these 10 stocks: Parabilis Medicines (+$53M), ACHV (+$50M), NAMS (+$39M), ALLO (+$39M), DSGN (+$26M), STTK (+$26M), Ascendis Pharma A S (+$25M), Kailera Therapeutics (+$24M), RLAY (+$19M), AURA (+$14M).
- Started 6 new stock positions in ACHV, STTK, Kailera Therapeutics, RLAY, Parabilis Medicines, DSGN.
- Reduced shares in these 5 stocks: BBIO (-$142M), Kalvista Pharmaceuticals (-$100M), RVMD (-$66M), AGIO (-$43M), TRVI.
- Sold out of its positions in AGIO, Kalvista Pharmaceuticals, RVMD.
- Frazier Life Sciences Management was a net seller of stock by $-11M.
- Frazier Life Sciences Management has $4.6B in assets under management (AUM), dropping by 18.15%.
- Central Index Key (CIK): 0001892134
Tip: Access up to 7 years of quarterly data
Positions held by Frazier Life Sciences Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 41 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals (MIRM) | 19.6 | $899M | 7.7M | 117.07 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 13.3 | $613M | +6% | 18M | 33.89 |
|
| Erasca (ERAS) | 10.0 | $458M | 25M | 18.32 |
|
|
| Mbx Biosciences (MBX) | 8.0 | $367M | 6.7M | 55.20 |
|
|
| Arcutis Biotherapeutics (ARQT) | 5.6 | $259M | 9.9M | 26.22 |
|
|
| Trevi Therapeutics (TRVI) | 4.0 | $185M | 9.9M | 18.65 |
|
|
| Krystal Biotech (KRYS) | 3.9 | $179M | 481k | 371.67 |
|
|
| Maze Therapeatics (MAZE) | 3.3 | $150M | +10% | 5.0M | 29.84 |
|
| Phathom Pharmaceuticals (PHAT) | 2.9 | $135M | 13M | 10.85 |
|
|
| Palvella Therapeutics Inc Ne (PVLA) | 2.9 | $135M | 882k | 152.82 |
|
|
| Bridgebio Pharma (BBIO) | 2.5 | $115M | -55% | 1.5M | 74.48 |
|
| Disc Medicine (IRON) | 2.2 | $99M | 1.4M | 73.14 |
|
|
| Cytokinetics Com New (CYTK) | 2.2 | $99M | 1.2M | 85.19 |
|
|
| Dyne Therapeutics (DYN) | 1.5 | $70M | 3.2M | 22.21 |
|
|
| Ascendis Pharma A/s Sponsored Adr | 1.3 | $60M | +68% | 225k | 266.72 |
|
| Savara (SVRA) | 1.3 | $60M | 9.7M | 6.16 |
|
|
| Parabilis Medicines | 1.1 | $53M | NEW | 1.9M | 27.37 |
|
| Aura Biosciences (AURA) | 1.1 | $50M | +39% | 7.1M | 7.10 |
|
| Achieve Life Sciences (ACHV) | 1.1 | $50M | NEW | 7.6M | 6.53 |
|
| Vor Biopharma Com New (VOR) | 1.0 | $47M | 2.5M | 18.41 |
|
|
| Allogene Therapeutics (ALLO) | 1.0 | $47M | +491% | 22M | 2.08 |
|
| Tarsus Pharmaceuticals (TARS) | 1.0 | $46M | 729k | 62.94 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 0.9 | $40M | 4.0M | 10.00 |
|
|
| Alkermes SHS (ALKS) | 0.8 | $37M | 701k | 52.40 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 0.8 | $36M | 1.4M | 25.30 |
|
|
| Zai Lab Adr (ZLAB) | 0.8 | $36M | 1.9M | 19.00 |
|
|
| Mannkind Corp Com New (MNKD) | 0.6 | $28M | +11% | 6.6M | 4.26 |
|
| Design Therapeutics (DSGN) | 0.6 | $26M | NEW | 1.8M | 14.47 |
|
| Aclaris Therapeutics (ACRS) | 0.6 | $26M | 4.9M | 5.29 |
|
|
| Shattuck Labs (STTK) | 0.6 | $26M | NEW | 3.8M | 6.94 |
|
| Kailera Therapeutics Common Stock | 0.5 | $24M | NEW | 1.1M | 22.03 |
|
| Monte Rosa Therapeutics (GLUE) | 0.5 | $24M | 1.0M | 24.20 |
|
|
| Lexeo Therapeutics (LXEO) | 0.5 | $23M | +9% | 4.8M | 4.66 |
|
| Relay Therapeutics (RLAY) | 0.4 | $19M | NEW | 1.0M | 18.71 |
|
| Evolus (EOLS) | 0.4 | $18M | 2.6M | 6.94 |
|
|
| Immunocore Hldgs Ads (IMCR) | 0.3 | $15M | 485k | 31.75 |
|
|
| Valneva Se Sponsored Ads (VALN) | 0.3 | $12M | 2.3M | 5.23 |
|
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.2 | $11M | 500k | 21.37 |
|
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.2 | $7.1M | 4.4M | 1.60 |
|
|
| Xilio Therapeutics (XLO) | 0.1 | $4.0M | 423k | 9.58 |
|
|
| Ibio Com New (IBIO) | 0.1 | $3.4M | 2.0M | 1.75 |
|
Past Filings by Frazier Life Sciences Management
SEC 13F filings are viewable for Frazier Life Sciences Management going back to 2022
- Frazier Life Sciences Management 2026 Q2 filed Aug. 14, 2026
- Frazier Life Sciences Management 2026 Q1 filed May 15, 2026
- Frazier Life Sciences Management 2025 Q4 filed Feb. 13, 2026
- Frazier Life Sciences Management 2025 Q3 filed Nov. 14, 2025
- Frazier Life Sciences Management 2025 Q2 filed Aug. 14, 2025
- Frazier Life Sciences Management 2025 Q1 filed May 15, 2025
- Frazier Life Sciences Management 2024 Q4 filed Feb. 18, 2025
- Frazier Life Sciences Management 2024 Q3 filed Nov. 15, 2024
- Frazier Life Sciences Management 2024 Q2 filed Aug. 15, 2024
- Frazier Life Sciences Management 2024 Q1 filed May 15, 2024
- Frazier Life Sciences Management 2023 Q4 filed Feb. 14, 2024
- Frazier Life Sciences Management 2023 Q3 filed Nov. 14, 2023
- Frazier Life Sciences Management 2023 Q2 filed Aug. 14, 2023
- Frazier Life Sciences Management 2023 Q1 filed May 15, 2023
- Frazier Life Sciences Management 2022 Q4 restated filed Feb. 7, 2023
- Frazier Life Sciences Management 2022 Q4 filed Feb. 3, 2023